Vabysmo

May 27, 2024

Retinal vein occlusion is the second most prevalent retinal vascular disease after diabetic retinopathy. Without treatment, it often results in a gradual decline in vision, ultimately causing permanent blindness. It ranks among the leading causes of vision loss globally, and this visual impairment significantly imp...

Nov 10, 2023

Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...